IQVIA (NYSE:IQV) Given New $255.00 Price Target at Barclays

IQVIA (NYSE:IQV) had its price objective decreased by stock analysts at Barclays from $260.00 to $255.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target points to a potential upside of 21.93% from the stock’s previous close.

A number of other analysts have also recently issued reports on IQV. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday. Robert W. Baird decreased their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday. Finally, The Goldman Sachs Group cut their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $262.71.

IQVIA Stock Up 1.6 %

Shares of NYSE IQV traded up $3.31 during midday trading on Friday, hitting $209.13. 893,041 shares of the company’s stock were exchanged, compared to its average volume of 1,083,172. The company has a market cap of $38.12 billion, a PE ratio of 27.08, a P/E/G ratio of 2.11 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA has a twelve month low of $181.03 and a twelve month high of $261.73. The firm’s fifty day simple moving average is $235.10 and its 200-day simple moving average is $229.89.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently made changes to their positions in the stock. Canada Pension Plan Investment Board increased its position in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the period. Lazard Asset Management LLC boosted its holdings in shares of IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after acquiring an additional 30,014 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after purchasing an additional 92,293 shares during the period. Finally, Capital Research Global Investors grew its holdings in IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after acquiring an additional 143,533 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.